By Kathryn Calkins
& Mike Ward
Staff Writers

If the case of Jarndyce v Jarndyce was sufficiently convoluted to keep Charles Dickens occupied for almost a thousand pages of Bleak House, the newly initiated legal wrangling between tiny Oxford Gene Technology Ltd. and Affymetrix Inc. is already so confusing that it requires a scorecard to tell the players.